
Surgery for early disease:
May involve removal of one or both ovaries and fallopian tubes, the uterus, omentum and other tissues required for accurate staging.

From diagnosis and treatment planning to surgery, recovery, maintenance and follow-up, experience care that considers your strength, nutrition, reproductive health, comfort and overall wellbeing.

A diagnosis can bring many questions at once. Let us begin with the basics.
Ovarian cancer develops when abnormal cells grow in or around the ovary and form a malignant tumour. It includes several tumour types that can behave differently. The main groups are epithelial ovarian cancer, germ-cell tumours and sex cord-stromal tumours, while borderline ovarian tumours have different biological behaviour. Epithelial ovarian cancer is the most common group. Ovarian epithelial, fallopian tube and primary peritoneal cancers are closely related and are often staged and treated similarly. Early disease may cause few symptoms. Assessment can involve imaging, CA-125 and other blood tests, followed by specialist review. A definitive diagnosis generally requires examination of tumour tissue to identify the exact cancer type.
Your gynaecologic oncologist may have discussed surgery, chemotherapy, maintenance treatment, targeted medicines or other systemic therapies. Treatment depends on tumour type, stage, whether complete surgery is possible, molecular findings, previous treatment, general health and fertility goals.
Treatment for recurrence depends on previous treatment, duration of response, tumour biology and available targeted options.

Cancer Healer Therapy (CAM) is supportive integrative care used alongside treatment prescribed by your gynaecologic oncologist, not instead of it.
The supportive plan may consider appetite, fatigue, sleep, mobility, emotional wellbeing and recovery after surgery or systemic treatment.
Herbal medicines and supplements can interact with chemotherapy, bevacizumab, PARP inhibitors, immunotherapy, hormone therapy, blood thinners and medicines used around surgery.
Some products may also affect kidney or liver function, blood counts, bleeding or clotting risk, blood pressure and wound healing.
Support may begin before surgery or systemic therapy, with attention to abdominal symptoms, nutrition, bowel and urinary function, blood counts, organ function and fertility concerns.
Supportive care may focus on fatigue, appetite, nausea, bowel changes, abdominal discomfort, sleep difficulties, mobility and treatment-related stress.
Supportive care should not delay imaging, biopsy, surgery, chemotherapy, maintenance treatment, genetic testing or treatment for ascites or bowel obstruction.
Cancer Healer Therapy does not replace cytoreductive surgery, chemotherapy, PARP inhibitors, bevacizumab, immunotherapy, hormone therapy or treatment for cancer-related complications.
Ovarian cancer includes several tumour types that differ in behaviour and treatment.
Borderline ovarian tumours have abnormal cells but differ from invasive ovarian carcinoma in their biological behaviour.

Ovarian cancer is generally classified into four stages according to how far it has spread.
The stage, together with tumour type, surgical findings and other clinical factors, helps the gynaecologic oncology team determine the most appropriate treatment approach for each patient.

Ovarian cancer may cause few noticeable symptoms initially. Possible symptoms include:
These symptoms can have non-cancerous causes. New, persistent, frequent or worsening symptoms should be medically assessed, particularly when several occur together or represent a change from usual health.


Here’s exactly what happens from your first conversation with us to ongoing support during treatment.
We discuss your diagnosis, pathology, scans, tumour-marker results, symptoms and current or planned oncology treatment.
The team reviews tumour type, stage, surgical findings, CA-125 when informative, BRCA or HRD findings, fertility concerns and treatment plan.
Supportive care is developed around the treatment recommended by your gynaecologic oncology team.
Herbal medicines, supplements and special diets should be disclosed to the treating doctor.
The plan may be reviewed as symptoms, blood tests, imaging and treatment needs change.
One point of contact supports appointments and follow-up communication.

Meet Dr. Tarang Krishna, MD - Cancer Healer Center
Dr. Tarang Krishna has spent over two decades developing and refining Cancer Healer Therapy, working with a multidisciplinary team across 30+ centres in India.
His work has been recognised for innovative cancer care and brings a coordinated, supportive approach to every patient journey.

Every cancer journey is personal. Read experiences shared by patients and families about the consultations, communication, follow-up and support they received at Cancer Healer Center.
4.9 Stars | 5479 Reviews
No. Most ovarian cysts are non-cancerous. Persistent, complex or enlarging masses may require specialist assessment.
They begin in different anatomical locations but epithelial ovarian, fallopian tube and primary peritoneal cancers are closely related and usually treated similarly.
No. CA-125 can increase because of several non-cancerous conditions, and some ovarian cancers do not cause a raised level.
Routine CA-125 or ultrasound screening is not generally recommended for average-risk people without symptoms. High-risk individuals need personalised genetic and specialist advice.
Sometimes. Fertility-preserving surgery may be possible for selected early epithelial cancers, borderline tumours, germ-cell tumours and sex cord-stromal tumours.
Debulking or cytoreductive surgery removes as much visible cancer as safely possible. It may be performed before chemotherapy or after initial chemotherapy.
Maintenance treatment is given after initial chemotherapy has controlled the cancer. Depending on tumour biology, it may include a PARP inhibitor, bevacizumab or another selected treatment.
They can help identify inherited cancer risk and may influence eligibility for PARP inhibitor maintenance and other treatment decisions.
Yes. Treatment may include chemotherapy, surgery in selected patients, targeted or maintenance therapies, procedures for complications and supportive care.
No. Cancer Healer Therapy is supportive integrative care used alongside treatment prescribed by your gynaecologic oncology team. It should not replace or delay recommended cancer treatment.
Only after discussing every product with your gynaecologic oncologist or oncology pharmacist. Herbal products may interact with treatment or affect bleeding, blood counts, blood pressure, kidney or liver function.